

## [Eflornithine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.5. Antitrypanosomal medicines](#) [6.5.5.1. African trypanosomiasis](#) [6.5.5.1.2. Medicines for the treatment of 2nd stage African trypanosomiasis](#)

ATC codes: [P01CX03](#)

EMLc

Indication

Gambiense trypanosomiasis ICD11 code: [1F51.0](#)

INN

Eflornithine

Medicine type

Chemical agent

List type

Core

Additional notes

To be used for the treatment of *Trypanosoma brucei gambiense* infection.

Formulations

**Parenteral > General injections > IV:** 200 mg per mL in 50 mL bottle (hydrochloride)

EML status history

First added in 1991 ([TRS 825](#))

Changed in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Eflornithine](#)

DrugBank

[Eflornithine](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for eflornithine on the EML and EMLc be amended to change the bottle volume in which eflornithine is supplied from 100 mL to 50 mL.